What if clinical trials were no longer the bottleneck of drug development?
For decades, innovation has followed a familiar trajectory. Discovery has advanced rapidly within highly specialized research environments. Development has proceeded through increasingly complex and costly clinical trials, concentrated largely in high-income countries. Only later have therapies extended more broadly, often to populations that were underrepresented in the evidence base supporting regulatory approval.
That model is now under growing strain. Rising development costs, recruitment bottlenecks, fragmented regulatory pathways, and increasing expectations for population diversity are placing pressure on traditional approaches.
If we were designing today’s development infrastructure using current scientific tools and global health realities, we might construct it differently.
The pharmaceutical industry has accelerated dramatically in drug discovery. Artificial intelligence can now identify promising molecules in months rather than years. Genomic platforms enable increasingly precise targeting of disease pathways. mRNA technologies have demonstrated the capacity for rapid adaptation. Yet the development phase often remains comparatively fragmented: site networks operate independently, regulatory processes are repeated across jurisdictions, data systems lack interoperability, and enrollment delays slow the delivery of therapies.
If discovery can evolve rapidly, development can as well.
Africa offers a compelling context for that evolution.
The continent represents approximately 17 percent of the world’s population yet hosts a small proportion of global clinical trials. This disparity is frequently described as underrepresentation. It can also be viewed as an opportunity to design development systems with greater intentionality.
Africa is demographically young, epidemiologically diverse, and increasingly scientifically capable. Its disease burden spans infectious diseases, cardiometabolic conditions, oncology, maternal health, and emerging chronic illnesses. Its research workforce continues to expand. Regional regulatory harmonization efforts are advancing through institutions such as the Africa Centres for Disease Control and Prevention (Africa CDC) and the African Medicines Agency. Digital health adoption is accelerating across many health systems.
Africa is not a blank slate. It presents structural advantages for building interoperable, digital-first research systems while infrastructure is still evolving in many settings.
The opportunity, however, is not simply to conduct more trials on the continent. It is to integrate research more systematically into care delivery.
Imagine a future in which research capacity is embedded within major hospitals and primary care networks as a routine function. Where patients are consistently informed about relevant clinical studies and offered the opportunity to participate. Where de-identified data generated through care and research contributes to ongoing understanding of safety and effectiveness beyond initial approval.
In such a model, trials would not compete with care; they would reinforce it.
Integrated data systems, governed ethically and locally, could support real-world evidence platforms and advanced analytics. Trial protocols could be stress-tested using representative datasets before enrollment begins. Safety monitoring could be strengthened through pharmacovigilance systems embedded in care delivery. Development would become more continuous, supported by coordinated networks rather than episodic site activation.
Africa is well positioned to contribute to this model precisely because much of its research infrastructure is being built or strengthened today. Building interoperable systems from the outset can be less complex than retrofitting legacy architectures.
Demographics reinforce the strategic case. Africa currently contributes roughly 5 percent of global economic output, yet it will account for an increasing share of the world’s population in the coming decades. Investments in education, health systems, and scientific capacity will influence whether that demographic growth translates into sustained economic development. A healthy population is both a social and economic imperative.
Ensuring that medicines are evaluated rigorously and appropriately across African populations is therefore central to long-term resilience.
This is where coordinated site networks become essential.
Individual research sites, however capable, cannot transform development systems alone. Durable networks can. Pre-qualified, continuously trained, digitally connected sites operating under standardized procedures and aligned regulatory pathways can reduce startup timelines, strengthen data quality, and sustain capacity beyond any single study.
When implemented thoughtfully, such networks also strengthen health systems. Laboratory upgrades for trials improve routine diagnostics. Digital data systems enhance patient tracking and outcomes monitoring. Governance frameworks developed for regulatory compliance strengthen national oversight capacity. Rather than extracting data, this approach builds institutional capability.
For industry, this is a strategic consideration as much as a social one.
Regulators increasingly expect greater diversity in clinical trial populations. Recruitment pressures in traditional markets continue to intensify. Cost constraints remain significant. Engagement with coordinated African networks can provide access to high-prevalence conditions, treatment-naïve populations, and datasets that enhance global regulatory confidence and applicability.
Realizing this potential requires partnership rather than transaction. Fragmented, short-term engagements reproduce inefficiencies. Long-term collaboration with continent-led coordination platforms enables scale, predictability, and sustainability.
At the Africa Clinical Research Network (ACRN), we are working toward this vision: a digitally integrated, governance-driven network of African research sites designed to improve how multi-country clinical trials are conducted at scale. Our objective is not to serve as a peripheral extension of existing systems, but to contribute meaningfully to their evolution.
Clinical development will continue to change. Scientific advances and economic realities make that unavoidable.
The question is not whether the system will adapt, but how — and where.
If investments in research integration, digital infrastructure, regulatory harmonization, and scientific workforce development continue across the continent, Africa can play a defining role in shaping a more inclusive, efficient, and scientifically robust development ecosystem.
The future of global clinical trials does not need to replicate the past. It can be distributed, digitally enabled, ethically governed, and operationally coordinated.
Built intentionally, Africa can help shape that future.